Electronic Supplementary Material (ESI) for Catalysis Science & Technology. This journal is © The Royal Society of Chemistry 2024

Supporting Information

2,3-Diamino-4,5-diaryl cyclopentadienone iron carbonyl complexes as catalysts for reductive amination reactions

Lukas Körner, Dirk Bockfeld, Thomas Bannenberg, and Matthias Tamm*

Technische Universität Braunschweig, Institut für Anorganische und Analytische Chemie, Hagenring 30, 38106

Braunschweig (Germany). E-Mail: m.tamm@tu-braunschweig.de

Content

S1 Experimental Procedures1
S1.1 Materials and Methods1
S1.2 Synthesis of Diarylcyclopropenones 21
S1.3 Synthesis of 2,3-Diamino-4,5-diarylcyclopentadienones 3
S1.4 Synthesis of CPD Iron Tricarbonyl Complexes 4 4
S1.5 Synthesis of CPD Iron Dicarbonyl Acetonitrile Complexes 5 and 6
S1.6 Catalytic (Transfer-)Hydrogenation of Acetophenone10
S1.7 Catalytic Reductive Amination Reactions11
S1.7 Reductive Amination affording Sertraline14
S2 NMR spectra
S2.1 2,3-Dipiperidino-4,5-diphenylcylopentadienone (3a)
S2.2 2,3-Dipiperidino-4,5-bis(tertbutylphenyl)cylopentadienone (3b)
S2.3 2,3-Dipiperidino-4,5-bis(2,5-dimethylphenyl)cylopentadienone (3c)
S2.4 2,3-Dipiperidino-4,5-bis(4-(trifluoromethyl)phenyl)cylopentadienone (3d)
S2.5 (2,3-Dipiperidino-4,5-diphenylcylopentadienone)iron tricarbonyl (4a)
S2.6 (2,3-Dipiperidino-4,5-bis(4-tertbutylphenyl)cylopentadienone)iron tricarbonyl (4b) 28
S2.7 (2,3-Dipiperidino-4,5-bis(2,5-dimethylphenyl)cylopentadienone)iron tricarbonyl (4c) 30
S2.8 (2,3-Dipiperidino-4,5-bis(4-trifluoromethylphenyl)cylopentadienone)iron tricarbonyl (4d)
S2.9 (2,3-Dipiperidino-4,5-diphenylcylopentadienone)iron acetonitrile dicarbonyl (5a)
S2.10 (2,3-Dipiperidino-4,5-bis(4-tertbutylphenyl)cylopentadienone iron acetonitrile
S2 11 (2.2 Diningriding 4.5 bic/2.5 dimethylphonyl)gylangatadiangno)iron acatonitrila
dicarbonyl (5c)
S2.12 (2,3-Dipiperidino-4,5-bis(4-trifluoromethylphenyl)cylopentadienone)iron acetonitrile dicarbonyl (5d)
S2.13 (1,4-dimethyl-5,7-diphenyl-1,2,3,4-tetrahydro-6H-cyclopenta[b]pyrazin-6-one)iron acetonitrile dicarbonyl (6)
S2.14 Products of the Catalytic Reductive Aminations
S3 Crystallographic Details
S4 Computational details
S5 References

S1 Experimental Procedures

S1.1 Materials and Methods

Unless otherwise noted, all reactions have been performed in dry argon atmosphere in a Glove Box (MBraun 200B) or using a high vacuum line with common Schlenk techniques. Elevated temperatures were achieved by a silicone oil bath, whereas low temperatures were provided by an isopropanol cooling bath. Starting materials, including diphenylcyclopropenone (2a), were purchased from commercial sources (TCI, abcr, Merck, Roth, Alfa-Aesar) and if necessary purified by conventional techniques or dried over CaH₂. Compounds 1, 1 IVa 2 and 7 3 were prepared according to literature procedures. Solvents were dried either over Na/benzophenone, CaH₂ (chlorinated solvents) and distilled or dried by a SPS (solvent purification system) with subsequent degassing ("freeze-pump" or ultrasonic bath). They were stored in dry argon atmosphere over molecular sieves (4 Å). NMR spectra were recorded on Bruker AVII300, AVIIHD300 (300 MHz), AVIII400 (400 MHz), AVII500 (500 MHz) or AVII600 (600 MHz) if not indicated otherwise at ambient temperature. ¹H NMR spectra were calibrated to the residual undeuterated solvent signal (¹H NMR) and ¹³C{¹H} NMR spectra to the solvent signal itself. ¹⁹F NMR spectra were calibrated externally to CFCl₃. Coupling constants (J) are indicated in Hertz (Hz) and splitting patterns are specified as multiplett (m), singlet (s), doublet (d), triplet (t), quartet (q) or septett (sept). Elemental analyses were performed on a Vario Micro Cube System. The FTIR spectra were measured on a Vertex 70 device from Bruker either as an ATR spectrum (diamond ATR method with a Pike-MIRacle device) or as a transmission spectrum of a solution (liquid cuvette with potassium chloride window). High-resolution-mass-spectrometric-measurements (HRMS) were performed using a linear ion trap coupled with orbitrap mass analyser from ThermoFisher Scientific Inc. (LTQ-Orbitrap Velos) with a resolution of 100000 FWHM (at m/z = 400 amu) in MeOH spiked with 0.1 mg/mL tetradecyltrimethylammonium bromide as internal mass reference. Electrospray-measurements were performed in direct infusion mode using a custom made microspray-device mounted on a Proxeon nanospray ion source. Gas chromatographic measurements with mass spectrometric coupling (GC/MS) were performed on a Shimadzu GC-2010 Plus with GCMS-QP2010 SE MS detector (positive El mode, 70 eV, 60-700 m/z). The injection was carried out at a temperature of 250 °C followed by a holding time of the temperature program at 50 °C for three minutes. Heating was carried out at a rate of 12 °C/mL for 8 minutes until the final temperature of 300 °C was reached and the final temperature was maintained for a further 8 minutes. The column used (30 m x 0.25 mm, 0.25 µm film thickness) consisted of 5% phenyl arylene and 95% dimethylpolysiloxane. Helium (volume flow 1.5 mL/min) was used as carrier gas.

S1.2 Synthesis of Diarylcyclopropenones 2



Diarylcyclopropenones 2b (R = 4-tert-butyl) and **2c** (R = 2,4-dimethyl) were prepared according to slightly adapted literature procedures:^{4,5}

To a suspension of tetrachlorocyclopropene (0.28 mL, 1 eq.) and AlCl₃ (375.0 mg, 1 eq.) in DCM (5 mL) at -78 °C a solution of ^tBu-benzene (for **2b**, 2 eq., 0.87 mL) and *p*-xylene (for 2c, 2 eq., 0.69 mL), respectively, in DCM (1 mL) was added. The reaction mixture was warmed up to ambient temperature

overnight and treated with H_2O (10 mL). The aqueous layer was extracted with DCM (2 x 10 mL) and the combined organic layers were washed with brine. Drying over anhydrous MgSO₄ and removing the solvent in vacuum lead to the desired products as colourless to beige solids. **2b** was further purified by crystallization from *n*-hexane solution.



Bis(4-trifluormethylphenyl)cyclopropenone (2d) was synthesized in three steps according to slightly adapted literature procedures as follows:^{6–8}

A solution of 4-(bromomethyl)(trifluoromethyl)benzene (2.19 g, 1 eq.) and Fe₂(CO)₉ (5.0 g, 1.5 eq.) in noctane (50 mL) was heated to reflux for 18 h. After cooling to rt the precipitate was filtered off and extracted with hot toluene (3 x 20 mL). The solvents were removed in vacuum and the crude product was purified by column chromatography on neutral alumina (diethylether/n-hexane 2:5) affording 1,3bis(4-(trifluoromethyl)phenyl)propan-2-one. The dibenzylketone was dissolved in glacial acid and a solution of bromine (2.2 eq.) in glacial acid was added drop by drop. The reaction mixture was stirred overnight and H₂O (15 mL) was added and it was stirred for another 30 minutes, resulting in a sticky yellow precipitate which was isolated by decantation of the supernatant solution and dried in high vacuum. Crystallization from hot n-hexane solution gave the dibromoketone. The dibromoketone was dissolved in DCM (5 mL), added to a solution of NEt₃ (2.5 eq.) in DCM (20 mL) and stirred for 45 min. It was washed with 1 m HCl (2 x 25 mL) and brine (2 x 20 mL) and dried over anhydrous MgSO₄. The solvent was removed in vacuum and the crude product was purified by column chromatography on silica gel (ethylacetate/n-hexane 1:4) affording pure **2d** as a colorless solid.

S1.3 Synthesis of 2,3-Diamino-4,5-diarylcyclopentadienones 3

General procedure: To a solution of the corresponding diarylcyclopropenone **2** (1 eq.) in toluene (V_A) a solution of dipiperidinoacetylene in toluene (V_B) was added at temperature T. The reaction mixture was stirred for a time t during which the colour changed to deep purple. The solvent was removed in vacuum and the crude product was purified by flash chromatography on neutral alumina with *n*-hexane/diethylether as eluent to obtain the pure product as a purple solid.



2,3-Dipiperidino-4,5-diphenylcyclopentadienone (3a). 321.7 mg diphenylcyclopropenone (**2a**), 300.0 mg dipiperidinoacetylene, $V_A = 25$ mL, $V_B = 5$ mL, 300 mg dipiperidinoacetylene, $V_B = 5$ mL, T = rt, t = 30 min, eluent = diethylether, yield: 363.5 mg (58%).

¹**H-NMR** (500 MHz; CDCl₃): δ (ppm) = 7.24–7.18 (m, 3H, Ph), 7.16–7.14 (m, 2H, Ph), 7.09–7.02 (m, 5H, Ph), 3.20–3.15 and 3.01–2.97 (m, 2 x 4H, pip- α -CH₂), 1.52–1.37 (m, 12H, pip- β /γ-CH₂).

¹³C{¹H}-NMR (126 MHz; CDCl₃): δ (ppm) = 197.7 (C=O), 161.8 (C_q-pip), 142.0 (C_q), 134.8 (C_q), 131.2 (C_q), 130.5 (CH), 128.9 (CH), 128.5 (CH), 127.8 (CH), 127.7 (CH), 127.4 (C_q), 127.2 (CH), 116.8 (C_q-pip), 53.2 and 51.5 (pip- α -CH₂), 27.0 and 26.6 (pip- β -CH₂), 2 x 24.3 (pip- γ -CH₂).

IR (neat, ATR): \tilde{v} (cm⁻¹) = 2931 (m, CH), 2913 (m, CH), 2847 (m, CH), 1669 (m, C=C), 1623 (m, C=C), 1575 (s, C=O).

UV/Vis maximum (Et₂O): λ = 511 nm.

EA. Anal. calc. for C₂₇H₃₀N₂O: C 81.37, H 7.59, N 7.03; found: C 81.00, H 7.55, N 6.86.

HRMS (ESI, MeOH): exact mass calc. for C₂₇H₃₀N₂O: 398.23581; found: 398.23546 m/z.



2,3-Dipiperidino-4,5-bis(4-*tert*-butylphenyl)cyclopentadienone (3b). 414.0 mg bis(4-*tert*-butyl)phenylcyclopropenone (2b), 250 mg dipiperidinoacetylene, $V_A = 25$ mL, VB = 5 mL, T = rt, t = 16h, eluent = diethylether, yield: 464 mg (70%).

¹H-NMR (300 MHz; CDCl₃): δ (ppm) = 7.34–7.28 (m, 2H, Ar), 7.19–7.13 (m, 4H, Ar), 7.12–7.06 (m, 2H, Ar), 3.28–3.18 and 3.11–3.01 (m, 2 x 4H, pip- α -CH₂), 1.56–1.41 (m, 12H, pip- β/γ -CH₂), 1.32 and 1.24 (s, 2 x 9H, *t*Bu)

¹³C{¹H}-NMR (76 MHz; CDCl₃): δ (ppm) = 198.2 (C=O), 162.1 (C_q-pip), 150.8 (C_q), 149.8 (C_q), 141.4 (C_q), 131.8 (C_q), 130.1 (CH), 128.6 (CH), 128.3 (C_q), 126.6 (C_q), 125.3 (CH), 124.6 (CH), 116.7 (Cq-pip), 53.2 and 51.4 (pip- α -CH₂), 34.8 and 34.6 (C_q, ^tBu), 31.5 and 31.4 (CH₃, ^tBu), 27.0 and 26.6 (pip- β -CH₂), 2 x 24.3 (pip- γ -CH₂).

IR (neat, ATR): \tilde{v} (cm⁻¹) = 2961 (m, v(CH₃)), 2929 (s, v(CH)), 2985 (m, v(CH)), 2791 (w, v(CH₂)), 1682 (s, v(C=O)).

UV/Vis maximum (Et₂O): 508 nm.

HRMS (ESI, MeOH): exact mass calc. for $C_{35}H_{46}N_2O$ ·H⁺: 511.36884; found: 511.36780 m/z.



2,3-Dipiperidino-4,5-bis(2,5-dimethylphenyl)cyclopentadienone (3c). 341.1 mg bis(2,5-dimethylphenyl)cyclopropenone (**2c**), 250 mg dipiperidinoacetylene, $V_A = 25$ mL, $V_B = 5$ mL, T = rt, t = 16h, eluent = diethylether/n-hexane (1:1), yield: 223 mg (38 %).

IR (neat, ATR): \tilde{v} (cm⁻¹) = 2922 (m, v(CH₂)), 2851 (m, v(CH₂)), 1682 (s, v(C=O)).

UV/Vis maximum (Et₂O): λ = 506 nm.

EA. Anal. calc. for C₃₁H₃₈N₂O: C 81.89, H 8.42, N 6.16; found: C 81.41, H 8.44, N 5.74.

HRMS (ESI, MeOH): exact mass calc. for C₃₁H₃₈N₂O·H⁺: 455.30624; found: 455.30443 m/z.



2,3-Dipiperidino-4,5-bis(4-trifluormethylphenyl)cyclopentadienone (3d). 200 mg bis((*p*-trifluoromethyl)-phenyl)cyclopropenone (2d), 112.2 mg dipiperidinoacetylene, $V_A = 20$ mL, $V_B = 5$ mL, T = -50 °C to rt, t = 16h, eluent = diethylether, yield = 203 mg (65 %).

¹**H-NMR** (500 MHz; CDCl₃): δ (ppm) = 7.63–7.58 (dm, ³J_{H,H} = 8.2 Hz, 2H, Ar), 7.44–7.41 (dm, ³J_{H,H} = 8.2 Hz, 2H, Ar), 7.37–7.34 (dm, ³J_{H,H} = 8.2 Hz, 2H, Ar), 7.19–7.16 (dm, ³J_{H,H} = 8.2 Hz, 2H, Ar), 3.24–3.19 and 3.07–3.02 (m, 2 x 4H, pip-α-CH₂), 1.61–1.53 and 1.53–1.46 (m, 2 x 6H, pip-β/γ-CH₂).

¹³C{¹H}-NMR (126 MHz; CDCl₃): δ (ppm) = 196.3 (C=O), 142.3 (C_q-pip), 138.0–137.9 (m, C_{ipso}), 134.2–134.1 (m, C_{ipso}), 130.7 (*o*-CH), 130.3 (q, ${}^{2}J_{C,F}$ = 30.5 Hz, *C*-CF₃), 129.4 (q, ${}^{2}J_{C,F}$ = 30.5 Hz, *C*-CF₃), 129.1 (*o*-CH), 127.0 (C_q-Ar), 125.6 (q, ${}^{3}J_{C,F}$ = 3.8 Hz, *m*-CH), 124.9 (q, ${}^{3}J_{C,F}$ = 3.8 Hz, *m*-CH), 124.3 (q, ${}^{1}J_{C,F}$ = 272.2 Hz, CF₃), 124.1 (q, ${}^{1}J_{C,F}$ = 272.2 Hz, CF₃), 117.6 (C_q-pip), 53.2 and 51.6 (pip-α-CH₂), 26.9 and 26.6 (pip-β-CH₂), 24.2 and 24.1 (pip-γ-CH₂), .

¹⁹F{¹H}-NMR (377 MHz; CDCl₃): δ (ppm) = -63.0 (s), -63.1 (s).

IR (neat, ATR): \tilde{v} (cm⁻¹) = 2935 (m, v(CH₂)), 2852 (w, v(CH₂)), 1681 (m, v(C=O)).

HRMS (ESI, MeOH): exact mass calc. for C₂₉H₂₈F₆N₂O: 534.21058; found: 534.21025 m/z.

S1.4 Synthesis of CPD Iron Tricarbonyl Complexes 4

General procedure: A solution of the corresponding cyclopentadienone **3** (1 eq.) and $Fe_2(CO)_9$ (2 eq.) in toluene (V) was heated to 110 °C for 16h. The solvent was removed in vacuum and the crude product was purified by flash chromatography on neutral alumina with DCM as eluent to afford the pure product as a yellow solid.



[(2a)Fe(CO)₃] (4a). 363.5 mg cyclopentadienone 3a, 663.6 mg Fe₂(CO)₉, V = 40 mL, yield: 414 mg (84%).

¹**H-NMR** (500 MHz; CDCl₃): δ (ppm) = 7.43–7.38 (m, 2H, Ph), 7.36–7.30 (m, 3H, Ph), 7.20–7.15 (m, 2H, Ph), 7.08–7.03 (m, 3H, Ph), 3.66–3.49 and 3.40–3.30 (m, 2 x 2H, pip-α-CH₂), 2.95–2.76 (m, 4H, pip-α-CH₂), 1.77–1.57 and 1.47–1.32 (m, 2 x 6H, pip-β/γ-CH₂).

¹³C[¹H]-NMR (75 MHz; CDCl₃): δ (ppm) = 211.0 (C=O), 165.9 (C=O), 133.2 (*ipso*-C_q), 132.9 (CH), 131.8 (*ipso*-C_q), 131.0 (CH), 2 x 128.5 (2 x CH), 127.6 (CH), 127.0 (CH), 118.5 and 108.0 (C_q-pip), 82.6 and 74.1 (C_q-Ph), 50.7 and 49.6 (pip-α-CH₂), 2 x 25.8 (pip-β-CH₂), 24.3 and 23.8 (pip-γ-CH₂).

IR (neat, ATR): \tilde{v} (cm⁻¹) = 2938 (w, CH₂), 2853 (w, CH₂), 2031 (m, C≡O), 1973 (s, C≡O), 1643 (m, C=O).

EA. Anal. calc. for C₃₀H₃₀N₂O₄Fe: C 66.92, H 5.62, N 5.20; found: C 66.71, H 5.64, N 5.10.



[(3b)Fe(CO)₃] (4b). 169.0 mg cyclopentadienone **3b**, 240.7 mg Fe₂(CO)₁₂, V = 10 mL, yield: 143.0 mg (66%).

¹**H-NMR** (300 MHz; CDCl₃): δ (ppm) = 7.37–7.30 (m, 4H, Ar), 7.12–7.02 (m, 4H, Ar), 3.64–3.49 and 3.40–3.28 (m, 2 x 2H, pip- α -CH₂), 2.95–2.74 (m, 4H, pip- α -CH₂), 1.77–1.57 (m, 6H, pip- β /γ-CH₂), 1.44–1.32 (m, 15H, pip- β /γ-CH₂ and *t*Bu), 1.20 (s, 9H, *t*Bu).

¹³C{¹H}-NMR (75 MHz; CDCl₃): δ (ppm) = 211.1 (C=O), 165.8 (C=O), 151.6 and 149.6 (<u>C</u>-*t*Bu), 132.5 (CH), 130.4 (CH), 130.0 and 128.6 (*ipso*-C_q), 125.4 (CH), 124.5 (CH), 118.6 and 107.9 (C_q-pip), 82.5 and 74.0 (C_q-Ar), 50.7 and 49.5 (pip-α-CH₂), 34.8 and 34.5 (C_q, tBu), 31.5 and 31.3 (CH₃, *t*Bu), 25.8 (pip-β-CH₂), 24.3 and 23.9 (pip-γ-CH₂).

IR (neat, ATR): \tilde{v} (cm⁻¹) = 2922 (w, CH₂), 2856 (w, CH₂), 2031 (m, C=O), 1960 (s, C=O), 1636 (m, C=O).

EA. Anal. calc. for C₃₈H₄₆N₂O₄Fe[·]CHCl₃: C 60.83, H 6.15, N 3.64; found: C 60.38, H 6.09, N 3.57.



[(3c)Fe(CO)₃] (4c). 172.0 mg cyclopentadienone 3c, 275.2 mg Fe₂(CO)₉, V = 10 mL, yield: 183.0 mg (81%).

¹**H-NMR** (400 MHz; CDCl₃): δ (ppm) = 7.16 (s, 1H, *o*-CH), 7.13–7.09 and 7.06–7.01 (m, 2 x 1H, *m/p*-CH), 6.98–6.93 and 6.84–6.79 (m, 2 x 1H, *m/p*-CH), 6.53 (s, 1H, *o*-CH), 3.67–3.45 and 3.31–3.19 (m, 2 x 2H, pip-α-CH₂), 3.08–2.92 and 2.87–2.76 (m, 2 x 2H, pip-α-CH₂), 2.41 (s, 3H, CH₃), 2.38 (s, 3H, CH₃), 2.23 (s, 3H, CH₃), 1.92 (s, 3H, CH₃), 1.77–1.58 and 1.49–1.32 (m, 6H, pip-β/γ-CH₂).

¹³C[¹H]-NMR (101 MHz; CDCl₃): δ (ppm) = 211.3 (C=O), 164.4 (C=O), 136.3 (*o*-C_q), 135.9 (*ipso*-C_q), 135.6 (*o*-C_q), 134.9 (*o*-CH), 133.5 (*ipso*-C_q), 132.6 (*m*-C_q), 132.1 (*o*-CH), 131.0 (*m*-CH), 129.5 (*m*-CH), 129.4 (*m*-C_q), 129.2 (p-CH), 128.2 (p-CH), 119.4 and 108.7 (C_q-pip), 80.3 (C_q-Ar, only one peak with ${}^{3}J_{C,H}$ correlation to the *ortho*-proton in ${}^{1}H, {}^{13}C$ -HMBC could be observed), 51.1 and 48.1 (pip-α-CH₂), 2x 25.8 (pip-β-CH₂), 24.2 and 23.8 (pip-γ-CH₂), 22.3 (*o*-CH₃), 21.1 (*m*-CH₃), 20.8 (*o*-CH₃), 20.7 (*m*-CH₃).

IR (neat, ATR): v (cm⁻¹) = 2981 (w, CH₂), 2935 (w, CH₂), 2853 (w, CH₂), 2032 (m, C=O), 1975 (s, C=O), 1959 (s, C=O), 1635 (m, C=O).

EA. Anal. calc. for C₃₄H₃₈FeN₂O₄: C 68.69, H 6.44, N 4.71; found: C 68.11, H 6.51, N 4.60.



[(3d)Fe(CO)₃] (4d). 187.0 mg cyclopentadienone 3d, 254.5 mg Fe₂(CO)₉, V = 20 mL, yield: 171 mg (72 %).

¹**H-NMR** (600 MHz; CDCl₃): δ (ppm) = 7.67–7.61 (m, 2H, *m*-CH), 7.59–7.53 (m, 2H, *o*-CH), 7.37–7.31 (m, 2H, *m*-CH), 7.30–7.24 (m, 2H, *o*-CH), 3.67–3.48 and 3.39–3.28 (m, 2 x 2H, pip-α-CH₂), 2.95–2.75 (m, 4H, pip-α-CH₂), 1.78–1.58 and 1.49–1.32 (m, 2 x 6H, pip- β/γ -CH₂).

¹³C{¹H}-NMR (125 MHz; CDCl₃): δ (ppm) = 209.9 (C=O), 165.5 (C=O), 137.0 and 135.6 (C_q, *ipso*-Ar), 132.8 (*o*-CH), 130.7 (q, ${}^{2}J_{C-F}$ = 32.7 Hz, *C*-CF₃), 130.5 (*o*-CH), 128.6 (q, ${}^{2}J_{C-F}$ = 32.5 Hz, *C*-CF₃), 125.4 and 124.4 (m, *m*-CH), 123.8 (q, ${}^{1}J_{C-F}$ = 272.3 Hz, CF₃), 123.7 (q, ${}^{1}J_{C-F}$ = 272.6 Hz, CF₃), 118.2 and 108.5 (C_q-pip), 79.5 and 71.3 (C_q-Ar), 50.3 and 49.3 (pip-α-CH₂), 25.4 and 25.3 (pip-β-CH₂), 23.8 and 23.3 (pip-γ-CH₂).

¹⁹F{¹H}-NMR (471 MHz; CDCl₃): δ (ppm) = -63.1 (s), -63.3 (s).

IR (neat, ATR): \tilde{v} (cm⁻¹) = 2037 (s, C=O), 1967 (s, C=O), 1631 (m, C=O).

EA. Anal. calc. for C₃₂H₂₈F₆FeN₂O₄: C 56.99, H 4.18, N 4.15; found: C 56.87, H 4.28, N 4.05.

S1.5 Synthesis of CPD Iron Dicarbonyl Acetonitrile Complexes 5 and 6

General procedure: The corresponding iron tricarbonyl complex **4** (1 eq.) was dissolved in toluene (V_A) and a solution of trimethyl-*N*-oxide (1 eq.) in acetonitrile (V_B) was carefully added at ambient temperature by which a gas evolution could be observed. After stirring for 3h, the solvent was removed *in vacuo* remaining a sticky residue. It was crystallized from toluene/*n*-hexane or acetonitrile (V_C) at -40 °C to afford the desired complex as an orange solid.



 $[(3a)Fe(CO)_2(NCMe)]$ (5a). 200.0 mg 4a, 27.9 mg trimethyl-*N*-oxide, V_A = 10 mL, V_B = 1 mL, V_C (toluene/*n*-hexane) = 1 : 1.5 mL, yield = 120 mg (59 %).

¹H-NMR (500 MHz; dcm-d₂): δ (ppm) = 7.41–7.34 and 7.34–7.28 (m, 2H, *o*-CH), 7.27–7.19 and 7.09–7.02 (m, 3H, *m/p*-CH), 3.55–3.43 and 3.42–3.30 (m, 2 x 2H, pip-α-CH₂), 2.80 (br s, 4H, pip-α-CH₂), 2.20 (s, 3H, NCCH₃), 1.71–1.52 and 1.42–1.29 (m, 6H, pip-β/γ-CH₂).

¹³C{¹H}-NMR (126 MHz; dcm-d₂): δ (ppm) = 216.0 and 214.1 (C=O), 164.5 (C=O), 135.2 and 135.1 (*ipso*-C_q), 132.8 and 130.9 (*o*-CH), 128.0 (*m*-CH), 127.7 (*p*-CH), 127.4 (*m*-CH and N<u>C</u>CH₃), 126.0 (*p*-CH), 120.2 and 101.2 (C_q-pip), 82.6 and 73.0 (C_q-Ar), 51.2 and 50.5 (pip-α-CH₂), 26.9 and 26.5 (pip-β-CH₂), 24.8 and 24.4 (pip-γ-CH₂), 4.8 (NC<u>C</u>H₃).

IR (TM, THF): \tilde{v} (cm⁻¹) = 1981 (s, C=O), 1926 (s, C=O), 1617 (m, C=O).

EA. Anal. calc. for C₃₁H₃₃N₃O₃Fe: C 67.52, H 6.03, N 7.62; found: C 67.87, H 6.20, N 7.30.



 $[(3b)Fe(CO)_2(NCMe)]$ (5b). 200.0 mg 4b, 23.1 mg trimethyl *N*-oxide, V_A = 10 mL, V_B = 1 mL, V_C (toluene/*n*-hexane) = 2 : 4 mL, yield = 116 mg (57 %).

¹**H-NMR** (400 MHz; dcm-d₂): δ (ppm) = 7.31 (d, ${}^{3}J_{H,H}$ = 8.3 Hz, 2H, *m*-CH), 7.28–7.21 (m, 4H, *o/m*-CH), 7.10 (d, ${}^{3}J_{H,H}$ = 8.3 Hz, 2H, *o*-CH), 3.55–3.42 and 3.40–3.30 (m, 2 x 2H, pip-α-CH₂), 2.78 (br s, 4H, pip-α-CH₂), 2.20 (s, 3H, NCCH₃), 1.68–1.51 (m, 6H, pip-β/γ-CH₂), 1.38–1.27 (m, 15H, pip-β/γ-CH₂ and *t*Bu), 1.24 (s, 9H, *t*Bu).

¹³C{¹H}-NMR (101 MHz; dcm-d₂): δ (ppm) = 216.1 and 214.3 (C=O), 164.6 (C=O), 151.1 and 148.8 (<u>C</u>-*t*Bu), 132.5 (*m*-CH), 132.1 and 131.8 (*ipso*-C_q), 130.5 (*m*-CH), 127.4 (N<u>C</u>CH₃), 125.0 (*o*-CH), 124.4 (*o*-CH), 120.2 and 101.3 (C_q-pip), 82.6 and 73.2 (C_q-Ar), 51.3 and 50.5 (pip-α-CH₂), 34.8 and 34.6 (C_q, *t*Bu), 2 x 31.4 (CH₃, *t*Bu), 26.9 and 26.5 (pip-β-CH₂), 24.9 and 24.5 (pip-γ-CH₂), 4.8 (NC<u>C</u>H₃).

IR (TM, THF): \tilde{v} (cm⁻¹) = 1980 (s, C=O), 1923 (s, C=O), 1616 (m, C=O).

EA. Anal. calc. for C₃₉H₄₉FeN₃O₃: C 70.58, H 7.44, N 6.33; found: C 70.65, H 7.44, N 6.10.



 $[(3c)Fe(CO)_2(NCMe)]$ (5c). 135.0 mg 4c, 17.1 mg trimethyl-*N*-oxide, V_A = 10 mL, V_B = 1 mL, V_C (toluene/*n*-hexane) = 1 : 4 mL, yield = 71 mg (51 %).

¹**H-NMR** (500 MHz; dcm-d₂): δ (ppm) = 7.26 (s, 1H, *o*-CH), 7.06 (s, 1H, *o*-CH), 6.96–6.91 (m, 1H, m-CH), 6.91–6.85 (m, 2H, p-CH), 6.84–6.77 (m, 1H, m-CH), 3.56–3.36 and 2.87–2.69 (m, 2 x 4H, pip-α-CH₂), 2.29 (s, 3H, o-CH₃), 2.21 (s, 6H, m-CH₃ and CH₃CN), 2.18 (s, 3H, m-CH₃), 2.10 (s, 3H, o-CH₃), 1.73–1.51 and 1.43–1.29 (m, 2x 6H pip-β/γ-CH₂).

¹³C[¹H]-NMR (126 MHz; dcm-d₂): δ (ppm) = 217.4 and 214.1 (C=O), 163.6 (C=O), 136.8 (*ipso*-C_q), 135.2 (*o*-C_q), 135.1 (*ipso*-C_q), 134.7 (*m*-C_q), 134.3 (*o*-CH), 134.1 (*o*-C_q), 133.8 (*m*-C_q), 132.6 (*o*-CH), 130.2 (*p*-CH), 129.5 (*m*-CH), 128.4 (*p*-CH), 127.5 (*m*-CH), 127.4 (CH₃<u>C</u>N), 118.0 and 104.8 (C_q-pip), 80.3 (C_q-Ar, only one peak with ${}^{3}J_{C,H}$ correlation to the *ortho*-proton in ${}^{1}H, {}^{13}C$ -HMBC could be observed), 51.8 and 49.0 (pip-α-CH₂), 26.9 and 26.3 (pip-β-CH₂), 24.8 and 24.4 (pip-γ-CH₂), 21.3 (*m*-CH₃), 20.9 (*m*-CH₃), 20.7 (*o*-CH₃), 20.6 (*o*-CH₃), 4.7 (<u>C</u>H₃CN).

IR (TM, THF): \tilde{v} (cm⁻¹) = 1976 (s, C=O), 1922 (s, C=O), 1615 (s, C=O).

EA. Anal. calc. for C₃₅H₄₁FeN₃O₃: C 69.19, H 6.80, N 6.92; found: C 68.75, 6.96, 6.48.



[(3d)Fe(CO)₂(NCMe)] (5d). 100.0 mg 4d, 11.1 mg trimethyl-*N*-oxide, $V_A = 5$ mL, $V_B = 0.5$ mL, V_C (acetonitrile) = 1 mL, product was additionally washed with 5 portions of 0.5 mL cold *n*-hexane. Yield = 65 mg (64 %).

¹H-NMR (500 MHz; dcm-d₂): δ (ppm) = 7.58–7.50 (m, 4H,), 7.49–7.43 (m, 2H,), 7.35–7.29 (m, 2H,), 3.54–3.42 and 3.40–3.29 (m, 2 x 2H,), 2.90–2.74 (m, 4H,), 2.21 (s, 3H, CH₃CN), 1.72–1.52 and 1.43–1.29 (2 x 6H,).

¹³C{¹H}-NMR (126 MHz; dcm-d₂): δ (ppm) = 215.2 and 213.4 (C=O), 164.5 (C=O), 139.7 and 139.5 (*ipso*-C_q), 133.3 and 130.5 (*o*-CH), 129.9 (q, ²J_{C-F} = 32.4 Hz, <u>C</u>-CF₃), 127.8 (CH₃<u>C</u>N), 127.4 (q, ²J_{C-F} = 32.2 Hz, <u>C</u>-CF₃), 125.2 (q, ³J_{C-F} = 3.8 Hz, *m*-CH), 124.9 (q, ¹J_{C-F} = 271.4 Hz, CF₃), 124.6 (q, ¹J_{C-F} = 272.0 Hz, CF₃), 124.4 (q, f³J_{C-F} = 3.8 Hz, *m*-CH), 121.2 and 101.0 (C_q-pip), 80.9 and 70.0 (C_q-Ar), 51.3 and 50.7 (pip-α-CH₂), 26.9 and 26.4 (pip-β-CH₂), 24.7 and 24.3 (pip-γ-CH₂), 4.8 (<u>C</u>H₃CN).

¹⁹F{¹H}-NMR (471 MHz; CDCl₃): δ (ppm) = -62.7, -62.8.

IR (TM, THF): \tilde{v} (cm⁻¹) = 1987 (s, C=O), 1932 (s, C=O), 1623 (s, C=O).

EA. Anal. calc. for C₃₃H₃₁F₆FeN₃O₃: C 57.66, H 4.55, N 6.11; found: C 57.25, H 4.43, N 5.83.



[(II)Fe(CO)₂NCMe] (6). The 3,4-diamino-2,5-diphenylcyclo-pentadienone II and [(II)Fe(CO)₃] were prepared according to literature procedures.^{9,10} Then, **6** was prepared according to the general procedure for the CPD iron dicarbonyl acetonitrile complexes: 100 mg [(II)Fe(CO)₃], 17.6 mg trimethyl-*N*-oxide, $V_A = 5$ mL, VB = 0.5 mL, V_C (toluene/*n*-hexane) = 5 : 8 mL, yield = 83 mg (75%).

¹H-NMR (300 MHz; dcm-d₂): δ (ppm) = 7.61–7.52 (m, 4H, Ph), 7.44–7.29 (m, 6H, Ph), 3.26–3.14 and 2.69–2.58 (m, 2 x 2H, NCH₂), 2.25 (s, 6H, NCH₃), 2.14 (s, 3H, CH₃CN).

¹³C{¹H}-NMR (76 MHz; dcm-d₂): δ (ppm) = 214.8 (C=O), 164.1 (C=O), 135.0 (*i*-Ph), 132.7 and 128.4 (*o*/*m*-Ph), 127.4 (*p*-Ph), 125.8 (CH₃CN), 111.6 (C_q-N), 70.1 (C_q-Ph), 50.1 (CH₃-N), 41.5 (CH₂-N), 4.6 (CH₃CN).

IR (TM, THF): \tilde{v} (cm⁻¹) = 1970 (s, C=O), 1909 (s, C=O), 1627 (s, C=O).

EA. Anal. calc. for C₂₅H₂₃FeN₃O₃: C 63.98, H 4.94, N 8.95; found: C 64.43, H 4.93, N 8.45.

S1.6 Catalytic (Transfer-)Hydrogenation of Acetophenone

Pressure-Hydrogenation (PH): Acetophenone (60.0 mg, 0.5 mmol, 1 Äq.), **5a** (2.8 mg, 1 mol%) and *n*-decane (10 mg) as internal standard were dissolved in toluene (2 mL), transferred in a Büchi[®] 20 mL "tiny clave" pressure reactor and a T_0 sample was taken. It was purged with hydrogen, charged with 3 bar and stirred at ambient temperature for 16h and a second sample was taken. The conversion was determined by GC/MS: >99%.

Transfer-Hydrogenation (TH): Acetophenone (120.0 mg, 1.0 mmol, 1 Äq.), **5a** (11.0 mg, 2 mol%) and *n*-decane as internal standard were dissolved in isopropanol (2 mL) and a T_0 sample was taken. The reaction mixture was heated to 80 °C and samples were taken after certain times. The conversions were determined by GC/MS. Conversion after 16h: 93%.



Scheme S1: (Transfer-)Hydrogenation of acetophenone using 4a as precatalyst.



Figure S1: Time conversion diagram of the transfer-hydrogenation of acetophenone using 5a, IVa and 7 as precatalysts.²

S1.7 Catalytic Reductive Amination Reactions

Citronellal (8, 77.1 mg, 0.5 mmol, 1 eq.), the secondary amine (0.6 mmol, 1.2 eq.) and the precatalyst [Fe] in 1 mL EtOH were submitted to a Büchi[®] 20 mL "tiny clave" pressure reactor and charged with 5 bar hydrogen pressure (after flushing 4 times). The mixture was stirred at a certain temperature for 16h. DCM (10 mL) was added, and it was washed with a saturated NaHCO₃ solution (10 mL). It was dried over anhydrous MgSO₄ and the solvent was evaporated in vacuum. In case of incomplete conversion, the product was separated by column chromatography on silica gel (*n*-hexane/ethylacetate), yielding the products as yellow to colourless oils.



N-benzyl-*N*-3,7-trimethyloct-6-en-1-amine (10). Yield: 115 mg (89%). The NMR data fits to those reported in the literature.¹¹

¹**H-NMR** (300 MHz; CDCl₃): δ (ppm) = 7.39-7.24 (m, 5H, CH_{Ar}), 5.20-5.09 (m, 1H, <u>*H*</u>C=CMe₂), 3.59-3.45 (m, 2H, N-CH₂-Ph), 2.43 (t, ³J_{H,H} = 8.0 Hz, N-CH₂), 2.22 (s, 3H, N-CH₃), 2.11-1.93 (m, 2H, CH₂), 1.73 (s, 3H, =C(CH₃)₂), 1.64 (s, 3H, =C(CH₃)₂), 1.61-1.46 (m, 2H, CH₂), 1.44-1.29 (m, 2H, CH₂), 1.27-1.20 (m, 1H, C<u>*H*</u>-CH₃), 0.91 (d, ³J_{H,H} = 6.7 Hz, 3H, CH-C<u>*H*₃).</u>

¹³C{¹H}-NMR (76 MHz; CDCl₃): δ (ppm) = 139.4 (*i*-C_q), 131.2 (CH= \underline{C} Me₂), 129.2 (CH_{Ar}), 128.3 (CH_{Ar}), 127.0 (CH_{Ar}), 125.1 (H \underline{C} =CMe₂), 62.5 (N-CH₂-Ph), 55.7 (N-CH₂), 42.4 (N-CH₃), 37.4 (CH₂), 34.6 (CH₂), 31.0 (\underline{C} H-Me), 25.9 (C=C(\underline{C} H₃)₂), 25.6 ((=CH- \underline{C} H₂), 19.8 (CH- \underline{C} H₃), 17.8 (C=C(\underline{C} H₃)₂).



2-(4-(3,7-dimethyloct-6-en-1-yl)piperazin-1-yl)pyrimidine (11). Yield 144 mg (95%). The NMR data fits to those reported in the literature.¹²

¹**H-NMR** (300 MHz; CDCl₃): δ (ppm) = 8.30 (d, ${}^{3}J_{H,H}$ = 4.7 Hz, 2H, *m*-CH), 6.47 (t, ${}^{3}J_{H,H}$ = 4.7 Hz, 1H, *p*-CH), 5.13-5.05 (m, 1H, <u>H</u>C=CMe₂), 3.89-3.75 (m, 4H, N-CH₂), 2.54-2.45 (m, 4H, N-CH₂), 2.43-2.33 (m, 2H, CH₂), 2.05-1.89 (m, 2H, CH₂), 1.70-1.66 (m, 3H, =C(CH₃)₂), 1.61-1.58 (m, 3H, =C(CH₃)₂), 1.55-1.40 (m, 2H, CH₂), 1.40-1.26 (m, 2H, CH₂), 1.25-1.09 (m, 1H, C<u>H</u>-CH₃), 0.90 (d, ${}^{3}J_{H,H}$ = 6.4 Hz, 3H, CH-C<u>H₃</u>).

¹³C{¹H}-NMR (76 MHz; CDCl₃): δ (ppm) = 161.8 (*i*-C_q), 157.8 (*m*-CH), 131.3 (CH= \underline{C} Me₂), 124.9 (H \underline{C} =CMe₂), 109.9 (*p*-CH), 57.1 (N-CH₂), 53.4 (N-CH₂), 43.9 (N-CH₂), 37.4 (CH₂), 34.0 (CH₂), 31.3 (\underline{C} H-Me), 25.9 (C=C(\underline{C} H₃)₂), 25.5 (C=CH- \underline{C} H₂), 19.9 (CH- \underline{C} H₃), 17.8 (C=C(\underline{C} H₃)₂).



1-(3,7-dimethyloct-6-en-1-yl)-2-(methoxymethyl)pyrrolidine (12). Yield 119 mg (94%).

¹H-NMR (300 MHz; CDCl₃): δ (ppm) = 5.12–5.06 (m, 1H, <u>H</u>C=CMe₂), 3.44–3.39 (m, 1H, O–CH₂), 3.34 (s, 3H, OCH₃), 3.29–3.23 (m, 1H, O–CH₂), 3.17–3.10 (m, 1H, N–CH₂), 2.91–2.78 (m, 1H, N–CH₂), 2.58–2.48 (m, 1H, N–CH₂), 2.28–2.18 (m, 1H, N–CH₂), 2.18–2.08 (m, 1H, N–CH₂), 2.04–1.92 (m, 2H, =CH–C<u>H₂</u>) 1.92–1.82 (m, 1H, CH₂), 1.79–1.68 (m, 2H, CH₂), 1.67 (s, 3H, =C(C<u>H₃)₂), 1.66–1.60 (m, 1H, CH₂), 1.59 (s, 3H, =C(C<u>H₃)₂), 1.57–1.40 (m, 1H, C<u>H</u>–Me), 1.38–1.24 (m, 3H, CH₂), 1.22–1.10 (m, 1H, CH₂), 0.89/0.87 (2 x d, 3H, CH–C<u>H₃)</u>.</u></u>

¹³C{¹H}-NMR (76 MHz; CDCl₃): δ (ppm) = 131.2 (CH=<u>C</u>Me₂), 125.1 (H<u>C</u>=CMe₂), 76.5 (O-CH₂), 63.9/63.8 (N-CH), 59.2 (O-CH₃), 54.8/54.6 (N-CH₂), 54.0/53.8 (N-CH₂), 37.6/37.2 (CH₂), 36.0/35.9 (CH₂), 31.3/31.2 (<u>C</u>H-Me), 28.6 (CH₂), 25.9 (C=C(<u>C</u>H₃)₂), 25.7/25.6 (=CH-<u>C</u>H₂), 23.1/23.0 (CH₂), 20.0/19.8 (CH-<u>C</u>H₃), 17.8 (C=C(<u>C</u>H₃)₂).

HRMS (ESI, MeOH): exact mass calc. for C₁₆H₃₁NO[·]H⁺: 254.24839; found: 254.24800 m/z.



N,N-dibenzyl-3,7-dimethyloct-6-en-1-amine (16). Yield: 103 mg (61%).

¹H-NMR (400 MHz; CDCl₃): δ (ppm) = 7.39-7.35 (m, 4H, *o*-CH_{Ar}), 7.33-7.28 (m, 4H, *m*-CH_{Ar}), 7.25-7.20 (m, 2H, *p*-CH_{Ar}), 5.09-5.03 (m, 1H, <u>H</u>C=CMe₂), 3.59 (d, ²J_{H,H} = 13.6 Hz, 2H, N-CH₂-Ph), 3.51 (d, ²J_{H,H} = 13.6 Hz, 2H, N-CH₂-Ph), 2.46-2.40 (m, 2H, N-CH₂), 2.02-1.82 (m, 2H, CH₂), 1.69-1.67 (m, 3H, =C(CH₃)₂), 1.59-1.57 (m, 3H, =C(CH₃)₂), 1.56-1.42 (m, 2H, CH₂), 1.35-1.20 (m, 2H, CH₂), 1.13-1.03 (m, 1H, C<u>H</u>-CH₃), 0.76 (d, ³J_{H,H} = 6.6 Hz, 3H, CH-C<u>H₃</u>).

¹³C{¹H}-NMR (101 MHz; CDCl₃): δ (ppm) = 140.2 (*i*-C_q), 131.1 (CH= \underline{C} Me₂), 128.9 (CH_{Ar}), 128.2 (CH_{Ar}), 126.8 (CH_{Ar}), 125.1 (H \underline{C} =CMe₂), 58.5 (N-CH₂-Ph), 51.5 (N-CH₂), 37.3(CH₂), 34.2 (CH₂), 30.5 (\underline{C} H-Me), 25.9 (C=C(\underline{C} H₃)₂), 25.6 (C=CH- \underline{C} H₂), 19.8 (CH- \underline{C} H₃), 17.8 (C=C(\underline{C} H₃)₂).

HRMS (ESI, MeOH): exact mass calc. for C₂₄H₃₃N[·]H⁺: 336.26912; found: 336.26876.



N,N-diallyl-3,7-dimethyloct-6-en-1-amine (18). Yield: 104 mg (89%).

¹H-NMR (300 MHz; CDCl₃): δ (ppm) = 5.94-5.77 (m, 2H, <u>H</u>C=), 5.21-5.04 (m, 4H, HC=C<u>H</u>₂), 3.14-3.00 (m, 4H, allyl NCH₂), 2.04-1.88 (m, 2H, NCH₂), 1.68 (s, CH₃, =CMe₃), 1.60 (s, CH₃, =CMe₃), 1.56-1.07 (m, 5H, CH and $2 \times CH_2$), 0.87 (d, ³J_{H,H} = 0.87 Hz).

¹³C[¹H]-NMR (76 MHz; CDCl₃): δ (ppm) = 136.0 (H<u>C</u>=CH₂), 131.2 (CH=<u>C</u>Me₂), 125.0 (H<u>C</u>=CMe₂), 117.4 (HC=<u>C</u>H₂), 57.0 (allyl CH₂), 51.4 (N-CH₂), 37.4 (CH₂), 33.9 (CH₂), 31.1 (CH/CH₃), 25.9 (CH/CH₃), 25.6 (CH₂), 19.9 (CH/CH₃), 17.8 (CH/CH₃).

HRMS (ESI, MeOH): exact mass calc. for $C_{16}H_{29}N$ ·H⁺: 236.23783; found: 236.23740.



1,1'-((3,7-dimethyloct-6-en-1-yl)azanediyl)bis(propan-2-ol) (19). Yield: 131 mg (97%).

¹**H-NMR** (400 MHz; CDCl₃): δ (ppm) = 5.12–5.03 (m, 1H, C=CH), 3.87–3.73 (m, 2H, HOC<u>H</u>), 3.17–2.81 (br m, 2H, OH), 2.68–2.47 (m, 2H, N–CH₂), 2.46–2.29 (m, 4H, N–CH₂), 2.06–1.86 (m, 2H, =CH–C<u>H₂</u>), 1.68 and 1.59 (s, 2 x 3H, C=C(CH₃)₂), 1.54–1.20 (m, 5H, 2 x CH₂ and C<u>H</u>–Me), 1.16–1.09 (m, 6H, HOCH–C<u>H₃</u>), 0.90–0.85 (m, 3H, CH–C<u>H₃</u>).

¹³C[¹H]-NMR (101 MHz; CDCl₃): δ (ppm) = 131.8 (CH= \underline{C} Me₂), 125.1 (H \underline{C} =CMe₂), 77.7 (HOC \underline{H}), 65.9/65.7 (HOC \underline{H}), 64.4/64.3 (HOC \underline{H}), 64.3 (N-CH₂), 63.1/63.0 (N-CH₂), 54.2 (N-CH₂), 53.7/53.5 (N-CH₂), 37.8/37.6/37.3 (CH₂), 34.4 (CH₂), 31.2 (CH), 26.2 (C=C(\underline{C} H₃)₂), 25.9 (CH₂), 21.0/20.9 (HOCH- \underline{C} H₃), 20.6 (HOCH- \underline{C} H₃), 20.3/20.1/20.0 (\underline{C} H-Me), 18.1 (C=C(\underline{C} H₃)₂).

HRMS (ESI, MeOH): exact mass calc. for $C_{16}H_{33}NO_2$ ·H⁺: 272.25895; found: 272.25852 m/z.



.1-(3,7-dimethyloct-6-en-1-yl)indoline (20). Yield: 101 mg (79%).

¹**H-NMR** (300 MHz; CDCl₃): δ (ppm) = 7.10-7.03 (m, 2H, CH_{Ar}), 6.63 (td, ${}^{3}J_{H,H}$ = 7.4 Hz, ${}^{4}J_{H,H}$ = 1.0 Hz, 1H, CH_{Ar}), 6.50-6.45 (m, 1H, CH_{Ar}), 5.17-5.07 (m, 1H, C=CH), 3.40-3.26 (m, 2H, N–CH₂),

¹³C{¹H}-NMR (76 MHz; CDCl₃): δ (ppm) = 152.8 (C_q), 131.4 (CH= \underline{C} Me₂), 130.2 (C_q), 127.4 (CH), 124.9 (H \underline{C} =CMe₂), 124.5 (CH), 117.4 (CH), 107.0 (CH), 53.1 (N-CH₂), 47.3 (N-CH₂), 37.3 (CH₂), 34.1 (CH₂), 30.7 (\underline{C} H-Me), 28.7 (CH₂), 25.9 (C=C(\underline{C} H₃)₂), 25.6 (CH₂), 19.8 (CH- \underline{C} H₃), 17.8 (C=C(\underline{C} H₃)₂).

HRMS (ESI, MeOH): exact mass calc. for C₁₈H₂₇N·H⁺: 258.22218; found: 258.22156 m/z.

S1.7 Reductive Amination affording Sertraline



4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine (22):

Tetralone derivative **21** (200 mg, 0.69 mmol, 1 eq.) and molecular sieves (4 Å, 680 mg) were treated with a methylamine solution (2M in ethanol, 2.08 mL, 4.16 mmol, 6 eq.) and stirred at ambient temperature for 48h. DCM (6 mL) was added, it was filtrated over Celite and the solvent was removed in vacuum, yielding a colourless solid. GC/MS analysis confirmed full conversion towards the intermediate imine of which 152.1 mg (0.5 mmol) were dissolved in ethanol (0.5 mL) and submitted to a Büchi® 20 mL "tiny clave" pressure reactor. Precatalyst **5a** (5.5 mg, 2 mol%, in 0.5 mL ethanol) was added and the reactor was flushed 4 times with H₂, then pressured with 5 bar H₂ and heated to 85 °C. After stirring for 16h at that temperature, the pressure was released, DCM (2 mL) was added, it was filtrated over Celite, and the solvent was removed in vacuum. GC/MS analysis revealed full conversion of the imine and two products which could be identified as the two diastereomers of **22** were detected. The ratio was determined according to the signal integrals, analogous to literature procedures.¹³ Comparison with the retention time of a (S,S)-**22** (*cis*-diastereomer) sample, which was obtained by deprotonation of Sertralin HCI (1A Pharma GmbH) with NaOH solution, allowed the assignment of the diastereomers.

Recorded NMR spectra fit to those of the cis and trans diastereomers reported in the literature (Figure 47 and 48).¹⁴

S2 NMR spectra

S2.1 2,3-Dipiperidino-4,5-diphenylcylopentadienone (3a)













Figure S3: ¹³C{¹H} NMR spectrum (CDCl₃, 126 MHz) of **3a**.



S2.2 2,3-Dipiperidino-4,5-bis(tertbutylphenyl)cylopentadienone (3b)

Figure S4: ¹H NMR spectrum (CDCl₃, 300 MHz) of **3b**.



Figure S5: ¹³C{¹H} NMR spectrum (CDCl₃, 76 MHz) of **3b**.



Figure S6: ¹H NMR spectrum at 100 °C (C₂D₂Cl₄, 500 MHz) of 3c.



Figure S7: ${}^{13}C{}^{1}H$ NMR spectrum (C₂D₂Cl₄, 126 MHz) of **3c**.



Figure S8: Variable temperature ¹H NMR spectrum (C₂D₂Cl₄, 500 MHz) of 3c.

0 0 0 0 .\ 1 -N Ń. Ń Ň *``* N-N-N-N 100 100

Figure S9: Atropisomers of 3c.

S2.4 2,3-Dipiperidino-4,5-bis(4-(trifluoromethyl)phenyl)cylopentadienone (3d)



Figure S10: ¹H NMR spectrum (CDCl₃, 500 MHz) of 3d.



Figure S11: ¹³C{¹H} NMR spectrum (CDCl₃, 126 MHz) of **3d**.







Figure S13: ¹H NMR spectrum (CDCl₃, 400 MHz) of 4a.



Figure S14: ¹³C{¹H} NMR spectrum (CDCl₃, 101 MHz) of 4a.



Figure S15: ¹H NMR spectrum (CDCl₃, 300 MHz) of 4b.



Figure S16: ¹³C{¹H} NMR spectrum (CDCl₃, 76 MHz) of 4b.



Figure S17: ¹H NMR spectrum (CDCl₃, 400 MHz) of **4c**.



Figure S18: $^{13}C{^{1}H}$ NMR spectrum (CDCl₃, 101 MHz) of 4c.



Figure S19: ¹H NMR spectrum (CDCl₃, 500 MHz) of 4d.



Figure S20: ¹³C{¹H} NMR spectrum (CDCl₃, 126 MHz) of 4d.






S2.9 (2,3-Dipiperidino-4,5-diphenylcylopentadienone)iron acetonitrile dicarbonyl (5a)

Figure S22: ¹H NMR spectrum (CD₂Cl₂, 500 MHz) of 5a.



Figure S23: ¹³C{¹H} NMR spectrum (CD₂Cl₂, 126 MHz) of **5a**.



S2.10 (2,3-Dipiperidino-4,5-bis(4-tertbutylphenyl)cylopentadienone iron acetonitrile dicarbonyl (5b)

Figure S24: ¹H NMR spectrum (CD₂Cl₂, 400 MHz) of 5b.



Figure S25: ${}^{13}C{}^{1}H$ NMR spectrum (CD₂Cl₂, 101 MHz) of **5b**.

S2.11 (2,3-Dipiperidino-4,5-bis(2,5-dimethylphenyl)cylopentadienone)iron acetonitrile dicarbonyl (5c)



Figure S26: ¹H NMR spectrum (CD₂Cl₂, 500 MHz) of 5c.



Figure S27: ${}^{13}C{}^{1}H$ NMR spectrum (CD₂Cl₂, 126 MHz) of 5c.

- 3.36 - 3.35 - 3.35 3.34 $\lesssim ^{2.83}_{2.81}$ 5.32 1.66 1.65 1.63 1.63 1.63 1.58 1.57 1.57 ÇF3 F₃C =0 Ň٠ .Fe≺ oC g NCMe 3.92∄ 1.99∄ 2.004 3.00-T 6.52] 6.28] 2.20<u>4</u> 2.17<u>4</u> 4.25-3.0 3.5 8.5 8.0 7.5 7.0 5.0 4.5 4.5 4 4.0 2.5 2.0 1.5 1.0 0.5 0.0 6.5 6.0 5.5

S2.12 (2,3-Dipiperidino-4,5-bis(4-trifluoromethylphenyl)cylopentadienone)iron acetonitrile dicarbonyl (5d)

Figure S28: ¹H NMR spectrum (CD₂Cl₂, 500 MHz) of 5d.



Figure S29: ${}^{13}C{}^{1}H$ NMR spectrum (CD₂Cl₂, 126 MHz) of 5d.



-60.2 -60.4 -60.6 -60.8 -61.0 -61.2 -61.4 -61.6 -61.8 -62.0 -62.2 -62.4 -62.6 -62.8 -63.0 -63.2 -63.4 -63.6 -63.8 -64.0 -64.2 -64.4 -64.6 -64.8 -65.0 -65.2 -65.4 δ (ppm)

Figure S30: ¹⁹F{¹H} NMR spectrum (CDCl₃, 471 MHz) of **5d**.

S2.13 (1,4-dimethyl-5,7-diphenyl-1,2,3,4-tetrahydro-6H-cyclopenta[b]pyrazin-6-one)iron acetonitrile dicarbonyl (6)



Figure S31: ¹H NMR spectrum (CD_2Cl_2 , 300 MHz) of **6**.



Figure S32: ${}^{13}C{}^{1}H$ NMR spectrum (CD₂Cl₂, 76 MHz) of 6.



Figure S33: ¹H NMR spectrum (CDCl₃, 300 MHz) of **10**.



Figure S34: ¹³C{¹H} NMR spectrum (CDCl₃, 76 MHz) of **10**.



Figure S35: ¹H NMR spectrum (CDCl₃, 300 MHz) of **11**.



Figure S36: ¹³C{¹H} NMR spectrum (CDCl₃, 300 MHz) of **11**.



Figure S37: ¹H NMR spectrum (CDCl₃, 400 MHz) of **12**.



Figure S38: ¹³C{¹H} NMR spectrum (CDCl₃, 101 MHz) of **12**.



Figure S39: ¹H NMR spectrum (CDCl₃, 400 MHz) of **16**.



Figure S40: ¹³C{¹H} NMR spectrum (CDCl₃, 101 MHz) of **16**.



Figure S41: ¹H NMR spectrum (CDCl₃, 300 MHz) of **18**.



Figure S42: ¹³C{¹H} NMR spectrum (CDCl₃, 76 MHz) of **18**.



Figure S43: ¹H NMR spectrum (CDCl₃, 400 MHz) of **19**.



Figure S44: ${}^{13}C{}^{1}H$ NMR spectrum (CDCl₃, 101 MHz) of **19**.



Figure S45: ¹H NMR spectrum (CDCl₃, 300 MHz) of 20.



Figure S46: ¹³C{¹H} NMR spectrum (CDCl₃, 76 MHz) of 20.



Figure S47: ¹H NMR spectrum (CDCl₃, 300 MHz) of 22.



Figure S48: ${}^{13}C{}^{1}H$ NMR spectrum (CDCl₃, 76 MHz) of 22.

S3 Crystallographic Details

Crystals were mounted on top of a human hair (**3a**, **4a**, **4b**·CHCl₃, **4c**, **4d**·C₆H₁₂, **5a**·0.5C₇H₈, **5b**·0.5C₆H₁₄, **5d**·MeCN and **6**) or on a Hampton Research CryoLoopTM (**3d** and **5c**·0.7C₅H₈·0.3C₆H₁₄) with perfluorinated inert oil. Data from compound **4a** were recorded with monochromated Mo-K α radiation on an Oxford Diffraction Xcalibur EOS diffractometer equipped with a CCD detector. All other data were recorded on Rigaku XtaLAB Synergy S Single Source diffractometers equipped with either a PhotonJet Cu-microfocus source (**3a**, **3d**, **4b**·CHCl₃ and **5d**·MeCN) or a PhotonJet Mo-microfocus source (**4c**, **4d**·C₆H₁₂, **5a**·0.5C₇H₈, **5b**·0.5C₆H₁₄, **5c**·0.7C₅H₈·0.3C₆H₁₄ and **6**) and a HyPix-6000HE detector. Data reduction was performed with CrysalisPro.¹⁵ Absorption correction was based on multi-scans and additionally face indexation and integration on a Gaussian grid was applied for **3d**, **4a**, **4b**·CHCl₃, **4c**, **4d**·C₆H₁₂, **5b**·0.5C₆H₁₄, **5c**·0.7C₅H₈·0.3C₆H₁₄, **5d**·MeCN and **6**. The structures were solved by intrinsic phasing with SHELXT-2018 ¹⁶ and refined on F² using the program SHELXL-2018 ¹⁷ in OLEX2.¹⁸ H atoms were placed in idealized positions and refined using a riding model.

Compound **3d** crystallized with two independent molecules in the asymmetric unit and was refined as non-merohedral twin. The second component (48.5 %) is rotated by -179.3° around the c axis. Two CF₃ groups exhibit rotational disorder and were described with a disorder model.

Compound **4d** crystallized as $4d \cdot C_6H_{12}$ with two independent molecules in the asymmetric unit and was refined as non-merohedral twin. The minor component (14.9 %) is rotated by -180° around [0.00 0.71 - 0.71] in reciprocal space or [0.21 0.93 -0.30] in direct space. Additionally, two CF₃ groups exhibiting rotational disorder were refined with a disorder model.

In $5a \cdot 0.5C_7H_8$ one phenyl ligand was found disordered and refined accordingly. Furthermore, the toluene molecule is refined to a s.o.f. of 0.5 and is disordered via the *c* glide plane.

5b crystallized as $5b \cdot 0.5C_6H_{14}$ with one half molecule of hexane in the asymmetric unit. One *tert*-butyl group of **5b** was refined with a disorder model. Additionally, the structure was refined as a non-merohedral twin with the minor component (42.9 %) rotated by 0.8° around [0.13 0.08 -0.99] (reciprocal) or [0.52 -0.01 -0.85] (direct).

In the crystals obtained from compound **5c** the solvent molecules were found disordered and refined with a disorder model comprising of 0.705 molecules of toluene and 0.295 molecules of n-hexane per asymmetric unit whereas two different orientations were identified for the toluene molecule. Chemically equivalent C-C distances have been restrained in these solvent molecules.

Compound **5d** crystallized as **5d**·MeCN and was refined as a non-merohedral twin. The second component (45.5%) is rotated by 0.9° around [0.28-0.940.21] (reciprocal) or [0.25-0.97-0.01] (direct). One CF₃ group was refined with a 3-component disorder model. Chemically equivalent C-F and F-F distances were restrained to be equal. Furthermore, 0.5 molecules of acetonitrile per Asymmetric unit have been identified but could not be refined satisfactorily. Therefore, a solvent mask, the Olex2 implementation of the program SQUEEZE ^[Spek, A. L. (2015). Acta Cryst. C71, 9-18.] has been used to mathematically remove the electron density of these molecules. 21 electrons were found in a volume of 129 Å³ in one void per unit cell which is consistent with the presence of 0.5 molecules of acetonitrile per Asymmetric Unit which account for 22 electrons per unit cell. The sum formula and derived parameters are based

on 0.5 molecules of acetonitrile per Asymmetric unit.

Complete data have been deposited with the Cambridge Crystallographic Data Centre under the CCDC numbers 2338289 – 2338299. These data can be obtained free of charge from http://www.ccdc.cam.ac.uk/.

	CCDC	2338289	
	Empirical formula	C ₂₇ H ₃₀ N ₂ O	
	Formula weight	398.53	
	Temperature	100(2) K	
	Wavelength	1.54184 Å	
	Crystal system	Monoclinic	
	Space group P21/c		
	Unit cell dimensions		
	<i>a</i> = 19.5712(6) Å	$\alpha = 90^{\circ}$	
	<i>b</i> = 5.91540(10) Å	<i>β</i> = 115.442(4)°	
	<i>c</i> = 20.8266(6) Å	γ = 90°	
Volume	2177.30(12) Å ³		
Ζ	4		
Density (calculated)	1.216 Mg/m ³		
Absorption coefficient	0.569 mm ⁻¹		
F(000)	856		
Crystal habitus	needle (brown)		
Crystal size	0.540 x 0.050 x 0.030 mm ³		
artheta range for data collection	2.500 to 77.378°		
Index ranges	-24 ≤ h ≤ 24, -7 ≤ k ≤ 5, -26 ≤ l ≤ 26		
Reflections collected	34754		
Independent reflections	4537[<i>R_{int}</i> = 0.0433]		
Completeness to ϑ = 67.684°	99.9 %		
Max. and min. transmission	1.00000 and 0.65030		
Data / restraints / parameters	4537 / 0 / 272		
Goodness-of-fit on F^2	1.025		
Final <i>R</i> indices $[l > 2\sigma(l)]$	$R_1 = 0.0367, wR_2 = 0.0886$		
R indices (all data)	$R_1 = 0.0440, wR_2 = 0.0926$		
Largest diff. peak and hole	0.266 and -0.184 e·Å ³		
Crystallisation Details:	from Et ₂ O / <i>n</i> -hexan, -40 °C		

Table S1. Crystal data and structure refinement of 3a.

Table S2.	Crystal	data	and	structure	refinemer	nt of 3d .
-----------	---------	------	-----	-----------	-----------	-------------------

	CCDC	2338290	
	Empirical formula	$C_{29}H_{28}F_6N_2O$	
	Formula weight	534.53	
	Temperature	100(2) K	
	Wavelength	1.54184 Å	
	Crystal system	Orthorhombic	
	Space group	Pbca	
	Unit cell dimensions		
	<i>a</i> = 18.6211(6) Å	<i>α</i> = 90°	
	<i>b</i> = 16.9942(4) Å	<i>β</i> = 90°	
	<i>c</i> = 32.0027(8) Å	γ = 90°	
Volume	10127.3(5) Å ³		
Ζ	16		
Density (calculated)	1.402 Mg/m ³		
Absorption coefficient	0.990 mm ⁻¹		
F(000)	4448		
Crystal habitus	plate (brown)		
Crystal size	0.100 x 0.050 x 0.030 mm ³		
ϑ range for data collection	2.761 to 76.274°		
Index ranges	-23 ≤ h ≤ 23, -21 ≤ k ≤ 21, -39 ≤ l ≤ 39		
Reflections collected	26477		
Independent reflections	26477		
Completeness to ϑ = 67.684°	99.6 %		
Max. and min. transmission	1.000 and 0.845		
Data / restraints / parameters	26477 / 42 / 742		
Goodness-of-fit on F ²	1.015		
Final R indices $[l > 2\sigma(l)]$	$R_1 = 0.0622, wR_2 = 0.1503$		
R indices (all data)	$R_1 = 0.1081, wR_2 = 0.1727$		
Largest diff. peak and hole	0.385 and -0.255 e·Å³		
Crystallisation Details:	from <i>n</i> -hexane, -40 °C		

Table S3. Crystal data and structure refinement of 4a.

	CCDC	2338291	
	Empirical formula	$C_{30}H_{30}FeN_2O_4$	
	Formula weight	538.41	
	Temperature	110(2) K	
	Wavelength	0.71073 Å	
	Crystal system	Monoclinic	
	Space group	P21/n	
	Unit cell dimensions		
	<i>a</i> = 9.5244(5) Å	<i>α</i> = 90°	
	<i>b</i> = 27.7280(10) Å	<i>β</i> = 114.029(7)°	
	<i>c</i> = 10.4699(5) Å	γ = 90°	
Volume	2525.4(2) Å ³		
Ζ	4		
Density (calculated)	1.416 Mg/m ³		
Absorption coefficient	0.637 mm ⁻¹		
F(000)	1128		
Crystal habitus	irregular (yellow)		
Crystal size	0.330 x 0.280 x 0.200 mm ³		
ϑ range for data collection	2.253 to 30.996°		
Index ranges	-13 ≤ <i>h</i> ≤ 13, -40 ≤ <i>k</i> ≤ 40, -14 ≤ <i>l</i> ≤ 15		
Reflections collected	58781		
Independent reflections	8034[<i>R_{int}</i> = 0.0748]		
Completeness to ϑ = 25.242°	100.0 %		
Max. and min. transmission	0.950 and 0.859		
Data / restraints / parameters	8034 / 0 / 334		
Goodness-of-fit on <i>F</i> ²	1.046		
Final R indices $[l > 2\sigma(l)]$	$R_1 = 0.0417, wR_2 = 0.0900$		
R indices (all data)	$R_1 = 0.0638, wR_2 = 0.1007$		
Largest diff. peak and hole	0.494 and -0.425 e·Å ³		
Crystallisation Details:	THF / <i>n</i> -hexane, rt		

Table S4. Crystal data and structure refinement of 4b·CHCl₃.

	CCDC	2338292	
	Empirical formula	$C_{39}H_{47}CI_3FeN_2O_4$	
	Formula weight	769.98	
	Temperature	100(2) K	
	Wavelength	1.54184 Å	
	Crystal system	Triclinic	
	Space group	PĪ	
	Unit cell dimensions		
	<i>a</i> = 12.3708(3) Å	α = 99.388(2)°	
	<i>b</i> = 12.4378(2) Å	<i>β</i> = 97.450(2)°	
	<i>c</i> = 13.3652(3) Å	γ = 109.190(2)°	
Volume	1878.73(7) Å ³		
Ζ	2		
Density (calculated)	1.361 Mg/m ³		
Absorption coefficient	5.516 mm ⁻¹		
F(000)	808		
Crystal habitus	fragment of block (yellow)		
Crystal size	0.290 x 0.100 x 0.090 mm ³		
ϑ range for data collection	3.419 to 77.751°		
Index ranges	-13 ≤ <i>h</i> ≤ 15, -15 ≤ <i>k</i> ≤ 15, -16 ≤ <i>l</i> ≤ 16		
Reflections collected	81045		
Independent reflections	7933[<i>R_{int}</i> = 0.0364]		
Completeness to ϑ = 67.684°	100.0 %		
Max. and min. transmission	1.000 and 0.331		
Data / restraints / parameters	7933 / 0 / 448		
Goodness-of-fit on F ²	1.083		
Final R indices $[l > 2\sigma(l)]$	$R_1 = 0.0322, wR_2 = 0.0859$		
R indices (all data)	$R_1 = 0.0326, wR_2 = 0.0862$		
Largest diff. peak and hole	0.801 and -0.701 e·Å ³		
Crystallisation Details:	from chloroform / <i>n</i> -hexane, +3 °C		

Table S5. Crystal data and structure refinement of 4c.

	CCDC	2338293	
	Empirical formula	C ₃₄ H ₃₈ FeN ₂ O ₄	
	Formula weight	594.51	
	Temperature	100(2) K	
	Wavelength	0.71073 Å	
	Crystal system	Triclinic	
	Space group	PĪ	
	Unit cell dimensions		
	<i>a</i> = 9.9427(2) Å	<i>α</i> = 105.1650(10)°	
	<i>b</i> = 10.8687(2) Å	<i>β</i> = 92.6020(10)°	
	<i>c</i> = 16.2473(3) Å	γ = 114.222(2)°	
Volume	1521.98(6) Å ³		
Ζ	2		
Density (calculated)	1.297 Mg/m ³		
Absorption coefficient	0.535 mm ⁻¹		
F(000)	628		
Crystal habitus	block (yellow)		
Crystal size	0.324 x 0.194 x 0.178 mm ³		
ϑ range for data collection	2.156 to 44.910°		
Index ranges	-19 ≤ <i>h</i> ≤ 19, -21 ≤ <i>k</i> ≤ 21, -32 ≤ <i>l</i> ≤ 32		
Reflections collected	250909		
Independent reflections	24953[<i>R_{int}</i> = 0.0408]		
Completeness to ϑ = 25.242°	99.8 %		
Max. and min. transmission	1.000 and 0.525		
Data / restraints / parameters	24953 / 0 / 374		
Goodness-of-fit on F ²	1.057		
Final R indices $[l > 2\sigma(l)]$	$R_1 = 0.0302, wR_2 = 0.0860$		
R indices (all data)	$R_1 = 0.0371, wR_2 = 0.0885$		
Largest diff. peak and hole	0.622 and -0.354 e∙ų		
Crystallisation Details:	tallisation Details: from hot <i>n</i> -hexane		

Table S6. Crystal data and structure refinement of $\textbf{4d} \cdot C_6 H_{12}.$

	CCDC	2338294	
	Empirical formula	$C_{38}H_{40}F_6FeN_2O_4$	
	Formula weight	758.57	
	Temperature	100(2) K	
A A A A A A A A A A A A A A A A A A A	Wavelength	0.71073 Å	
	Crystal system	Triclinic	
	Space group	PĪ	
	Unit cell dimensions		
and the	<i>a</i> = 10.59054(12) Å	$\alpha = 101.0985(12)^{\circ}$	
	<i>b</i> = 15.4277(2) Å	<i>β</i> = 99.2340(10)°	
	<i>c</i> = 23.2167(3) Å	γ = 103.2907(8)°	
Volume	3538.46(8) Å ³		
Ζ	4		
Density (calculated)	1.424 Mg/m ³		
Absorption coefficient	0.501 mm ⁻¹		
F(000)	1576		
Crystal habitus	irregular (yellow)		
Crystal size	0.400 x 0.230 x 0.017 mm ³		
ϑ range for data collection	2.020 to 40.327°		
Index ranges	-19 ≤ <i>h</i> ≤ 19, -28 ≤ <i>k</i> ≤ 28, -42 ≤ <i>l</i> ≤ 42		
Reflections collected	78215		
Independent reflections	78215		
Completeness to ϑ = 25.242°	99.9 %		
Max. and min. transmission	1.000 and 0.407		
Data / restraints / parameters	78215 / 144 / 976		
Goodness-of-fit on F ²	1.049		
Final R indices $[l > 2\sigma(l)]$	$R_1 = 0.0855, wR_2 = 0.2310$		
R indices (all data)	$R_1 = 0.1161, wR_2 = 0.2484$		
Largest diff. peak and hole	2.068 and -0.969 e∙ų		
Crystallisation Details:	from cyclohexane, rt		

	CCDC	2338295	
	Empirical formula	C _{34.50} H ₃₇ FeN ₃ O ₃	
	Formula weight	597.52	
	Temperature	100(2) K	
	Wavelength	0.71073 Å	
	Crystal system	Monoclinic	
	Space group	P21/c	
	Unit cell dimensions		
	<i>a</i> = 11.3890(5) Å	<i>α</i> = 90°	
	<i>b</i> = 28.6159(7) Å	<i>β</i> = 117.667(5)°	
\bigcirc	<i>c</i> = 10.6867(5) Å	γ = 90°	
Volume	3084.6(2) Å ³		
Ζ	4		
Density (calculated)	1.287 Mg/m ³		
Absorption coefficient	0.527 mm ⁻¹		
F(000)	1260		
Crystal habitus	irregular (yellow)		
Crystal size	0.200 x 0.130 x 0.100 mm ³		
artheta range for data collection	2.141 to 38.567°		
Index ranges	-19 ≤ <i>h</i> ≤ 19, -50 ≤ <i>k</i> ≤ 50, -18 ≤ <i>l</i> ≤ 18		
Reflections collected	202323		
Independent reflections	17413[<i>R_{int}</i> = 0.0723]		
Completeness to ϑ = 25.242°	99.9 %		
Max. and min. transmission	1.00000 and 0.84183		
Data / restraints / parameters	17413 / 42 / 445		
Goodness-of-fit on F ²	1.056		
Final R indices $[l > 2\sigma(l)]$	$R_1 = 0.0522, wR_2 = 0.1229$		
R indices (all data)	$R_1 = 0.0724, wR_2 = 0.1312$		
Largest diff. peak and hole	0.832 and -0.435 e·Å ³		
Crystallisation Details:	toluene / <i>n</i> -hexane, -40 °C		
Table S8. Crystal data and structure refinement of $\textbf{5b}{\cdot}0.5C_6H_{14}.$

Ø	CCDC	2338296
	Empirical formula	$C_{42}H_{56}FeN_3O_3$
	Formula weight	706.74
	Temperature	101(2) K
	Wavelength	0.71073 Å
Q porto porto	Crystal system	Triclinic
	Space group	ΡĪ
	Unit cell dimensions	
	<i>a</i> = 11.1854(5) Å	$\alpha = 86.447(4)^{\circ}$
\mathcal{T}	<i>b</i> = 12.6987(5) Å	<i>β</i> = 71.724(4)°
\bigcirc	<i>c</i> = 14.8312(7) Å	γ = 71.449(4)°
Volume	1894.75(16) Å ³	
Ζ	2	
Density (calculated)	1.239 Mg/m ³	
Absorption coefficient	0.440 mm ⁻¹	
F(000)	758	
Crystal habitus	plate (yellow)	
Crystal size	0.220 x 0.140 x 0.030 mm ³	
ϑ range for data collection	2.020 to 32.037°	
Index ranges	$-16 \le h \le 16, -18 \le k \le 18, -22 \le l \le 22$	
Reflections collected	25609	
Independent reflections	25609	
Completeness to ϑ = 25.242°	100.0 %	
Max. and min. transmission	1.000 and 0.589	
Data / restraints / parameters	25609 / 0 / 482	
Goodness-of-fit on F ²	1.089	
Final R indices $[I > 2\sigma(I)]$	$R_1 = 0.0847, wR_2 = 0.1506$	
R indices (all data)	$R_1 = 0.1178, wR_2 = 0.1632$	
Largest diff. peak and hole	0.749 and -0.620 e·Å ³	
Crystallisation Details:	from <i>n</i> -hexane, -40 °C	

Table S9. Crystal data and structure refinement of $5c \cdot 0.7C_5H_8 \cdot 0.3C_6H_{14}$.

	CCDC	2338297	
	Empirical formula	$C_{41.71}H_{50.77}FeN_3O_3$	
DR3	Formula weight	697.93	
<u>.</u>	Temperature	100(2) K	
Production - O	Wavelength	0.71073 Å	
	Crystal system	Monoclinic	
	Space group	P21/n	
	Unit cell dimensions		
	<i>a</i> = 11.1925(5) Å	<i>α</i> = 90°	
	<i>b</i> = 28.2554(8) Å	<i>θ</i> = 113.551(6)°	
E.	<i>c</i> = 12.9763(6) Å	γ = 90°	
Volume	3761.9(3) Å ³		
Ζ	4		
Density (calculated)	1.232 Mg/m ³		
Absorption coefficient	0.442 mm ⁻¹		
F(000)	1488		
Crystal habitus	irregular (orange)		
Crystal size	0.230 x 0.190 x 0.050 mm ³		
artheta range for data collection	2.112 to 32.577°		
Index ranges	-16 ≤ <i>h</i> ≤ 16, -42 ≤ <i>k</i> ≤ 42, -19 ≤ <i>l</i> ≤ 19		
Reflections collected	133590		
Independent reflections	13691[<i>R_{int}</i> = 0.0712]		
Completeness to ϑ = 25.242°	100.0 %		
Max. and min. transmission	1.000 and 0.516		
Data / restraints / parameters	13691 / 247 / 547		
Goodness-of-fit on F ²	1.125		
Final R indices $[l > 2\sigma(l)]$	$R_1 = 0.0675, wR_2 = 0.1425$		
R indices (all data)	$R_1 = 0.0916, wR_2 = 0.1516$		
Largest diff. peak and hole	0.833 and -0.784 e∙ų		
Crystallisation Details:	toluene / <i>n</i> -hexane, rt		

Table S10. Crystal data and structure refinement of 5d·MeCN.

	CCDC	2338298	
	Empirical formula	$C_{34}H_{32.50}F_6FeN_{3.50}O_3\\$	
	Formula weight	707.98	
	Temperature	100(2) K	
	Wavelength	1.54184 Å	
	Crystal system	Triclinic	
	Space group	ΡĪ	
	Unit cell dimensions		
	<i>a</i> = 10.7552(4) Å	$\alpha = 106.515(3)^{\circ}$	
	<i>b</i> = 11.5325(3) Å	<i>θ</i> = 110.781(4)°	
Θ Θ	<i>c</i> = 14.6781(6) Å	γ = 94.220(3)°	
Volume	1600.72(11) Å ³		
Ζ	2		
Density (calculated)	1.469 Mg/m ³		
Absorption coefficient	4.446 mm ⁻¹		
F(000)	730		
Crystal habitus	irregular (orange)		
Crystal size	0.200 x 0.160 x 0.060 mm ³		
ϑ range for data collection	3.415 to 80.574°		
Index ranges	-13 ≤ <i>h</i> ≤ 12, -14 ≤ <i>k</i> ≤ 14, -18 ≤ <i>l</i> ≤ 18		
Reflections collected	6848		
Independent reflections	6848		
Completeness to ϑ = 67.684°	99.9 %		
Max. and min. transmission	1.000 and 0.358		
Data / restraints / parameters	6848 / 127 / 474		
Goodness-of-fit on F ²	1.054		
Final <i>R</i> indices $[l > 2\sigma(l)]$	$R_1 = 0.0606, wR_2 = 0.1657$		
R indices (all data)	$R_1 = 0.0619, wR_2 = 0.1675$		
Largest diff. peak and hole	1.052 and -0.814 e⋅ų		
Crystallisation Details:	from MeCN, -40 °C		

	CCDC	2338299	
	Empirical formula	$C_{25}H_{23}FeN_3O_3$	
	Formula weight	469.31	
	Temperature	100(2) K	
	Wavelength	0.71073 Å	
	Crystal system	Monoclinic	
	Space group	P21/n	
	Unit cell dimensions		
\square	<i>a</i> = 7.1127(2) Å	<i>α</i> = 90°	
	<i>b</i> = 14.3100(4) Å	<i>β</i> = 98.189(3)°	
	<i>c</i> = 21.7165(6) Å	γ = 90°	
Volume	2187.83(11) Å ³		
Ζ	4		
Density (calculated)	1.425 Mg/m ³		
Absorption coefficient	0.722 mm ⁻¹		
F(000)	976		
Crystal habitus	block (yellow)		
Crystal size	0.120 x 0.090 x 0.070 mm ³		
ϑ range for data collection	2.370 to 37.924°		
Index ranges	-11 ≤ <i>h</i> ≤ 12, -23 ≤ <i>k</i> ≤ 24, -37 ≤ <i>l</i> ≤ 37		
Reflections collected	110079		
Independent reflections	$11282[R_{int} = 0.0561]$		
Completeness to ϑ = 25.242°	99.9 %		
Max. and min. transmission	1.000 and 0.712		
Data / restraints / parameters	11282 / 0 / 292		
Goodness-of-fit on F ²	1.056		
Final <i>R</i> indices $[l > 2\sigma(l)]$	$R_1 = 0.0356, wR_2 = 0.0942$		
R indices (all data)	$R_1 = 0.0484, wR_2 = 0.0987$		
Largest diff. peak and hole	0.604 and -0.292 e·Å ³		
Crystallisation Details:	from toluene / <i>n</i> -hexane, -40 °C		

Table S11. Crystal data and structure refinement of 6.

S4 Computational details

All calculations were performed using the density functional method ω B97XD,^[17] which includes a version of Grimme's D2 dispersion model as implemented in the program Gaussian16.^[18] For all main group elements (C, H, N and O) the People type all-electron triple- ζ basis set was used, extended by a set of polarisation functions 6-311G(d,p). Solvent effects were included by a continuum using a universal solvent model (SMD) for toluene.^[19] Harmonic vibrational frequencies are calculated to characterise the respective minima (without imaginary frequency) and transition state structures (with an imaginary frequency).

Compound		<i>Е_{ок}а /</i> [На]	<i>Е</i> _{298к} ^b / [На]	<i>Н</i> _{298К} ^b / [На]	G _{298к} ^b / [На]
dipiperidinoacetylene	(1)	-578.425735	-578.412254	-578.411310	-578.467284
diphenylcyclopropenone	(2a)	-652.515699	-652.503364	-652.502420	-652.556381
addition at C1	vdW	-1230.955753	-1230.928337	-1230.927393	-1231.016473
	TS1a	-1230.914031	-1230.887535	-1230.886591	-1230.973973
	IN1a	-1230.926302	-1230.900021	-1230.899077	-1230.985531
	TS2a	-1230.920877	-1230.894648	-1230.893704	-1230.981755
	(3a)	-1231.063883	-1231.038439	-1231.037494	-1231.120243
addition at C2	vdW	-1230.954483	-1230.927032	-1230.926088	-1231.015301
	TS1b	-1230.934096	-1230.907799	-1230.906855	-1230.993007
	IN1b	-1230.986645	-1230.960274	-1230.959330	-1231.045282
	TS2b	-1230.983863	-1230.958385	-1230.957441	-1231.039925

Table S12: Energies for all optimized structures.

^a DFT energy incl. ZPE.

 b standard conditions T = 298.15 K and p = 1 atm.



Figure S41: Calculated energy profile for the formation of 2,3-dipiperidinyl-4,5-diphenylcyclopentadienone (**3a**) from dipiperidinoacetylene (**1**) and diphenylcyclopropenone (**2a**), scaled to standard Gibbs free energies (ΔG°); standard enthalpies are given in square brackets.

S5 References

- 1 A. R. Petrov, C. G. Daniliuc, P. G. Jones and M. Tamm, A novel synthetic approach to diaminoacetylenes: structural characterization and reactivity of aromatic and aliphatic ynediamines, *Chem. Eur. J.*, 2010, **16**, 11804–11808.
- 2 L. Hackl, L. P. Ho, D. Bockhardt, T. Bannenberg and M. Tamm, Tetraaminocyclopentadienone Iron Complexes as Hydrogenation Catalysts, *Organometallics*, 2022, **41**, 836–851.
- 3 T. N. Plank, J. L. Drake, D. K. Kim and T. W. Funk, Air Stable, Nitrile Ligated (Cyclopentadienone)iron Dicarbonyl Compounds as Transfer Reduction and Oxidation Catalysts, *Adv. Synth. Catal.*, 2012, **354**, 597–601.
- 4 S. Staicu, I. G. Dinulescu, F. Chiraleu and M. Avram, Reactions of acetylenes with transition metals, *J. Organomet. Chem.*, 1976, **117**, 385–394.
- 5 C. M. Vanos and T. H. Lambert, Development of a catalytic platform for nucleophilic substitution: cyclopropenone-catalyzed chlorodehydration of alcohols, *Angew. Chem. Int. Ed.*, 2011, **50**, 12222–12226.
- 6 C. Reichardt, M. Eschner and G. Schäfer, Syntheses and UV-visible spectroscopic properties of new 'fluorophilic' fluorine- and perfluoroalkyl-substituted solvatochromic pyridinium N phenolate betaine dyes, *J. Phys. Org. Chem.*, 2001, **14**, 737–751.
- 7 J. Chen, B. Tang, X. Liu, G. Lv, Y. Shi, T. Huang, H. Xing, X. Guo, L. Hai and Y. Wu, Ruthenium(ii)catalyzed [5 + 1] annulation reaction: a facile and efficient approach to construct 6-ethenyl phenanthridines utilizing a primary amine as a directing group, *Org. Chem. Front.*, 2020, 7, 2944– 2949.
- 8 R. Li, B. Li, H. Zhang, C.-W. Ju, Y. Qin, X.-S. Xue and D. Zhao, A ring expansion strategy towards diverse azaheterocycles, *Nat. Chem.*, 2021, **13**, 1006–1016.
- 9 E. Haak, Ruthenium Complexes of Electronically Coupled Cyclopentadienone Ligands Catalysts for Transformations of Propargyl Alcohols, *Eur. J. Org. Chem.*, 2007, **2007**, 2815–2824.
- 10 T.-T. Thai, D. S. Mérel, A. Poater, S. Gaillard and J.-L. Renaud, Highly active phosphine-free bifunctional iron complex for hydrogenation of bicarbonate and reductive amination, *Chem. Eur. J.*, 2015, **21**, 7066–7070.
- 11 S. Hanada, E. Tsutsumi, Y. Motoyama and H. Nagashima, Practical access to amines by platinumcatalyzed reduction of carboxamides with hydrosilanes: synergy of dual Si-H groups leads to high efficiency and selectivity, *J. Am. Chem. Soc.*, 2009, **131**, 15032–15040.
- 12 Z. Wu, S. D. Laffoon and K. L. Hull, Asymmetric synthesis of γ-branched amines via rhodiumcatalyzed reductive amination, *Nat. Commun.*, 2018, **9**, 1185.
- 13 A. J. Blacker, S. Brown, B. Clique, B. Gourlay, C. E. Headley, S. Ingham, D. Ritson, T. Screen, M. J. Stirling, D. Taylor and G. Thompson, A Low-Waste Process To Sertraline By Diastereomeric Crystal Resolution and Waste Isomer Racemisation, *Org. Process Res. Dev.*, 2009, **13**, 1370–1378.
- 14 R. Kalshetti, V. Venkataramasubramanian, S. Kamble and A. Sudalai, Concise enantioselective synthesis of (+)-sertraline and (–)-CP-52002 using proline catalysis, *Tetrahedron Lett.*, 2016, **57**, 1053–1055.
- 15 Rigaku Oxford Diffraction, CrysAlisPRO Software System, versions 1.171.41.112a (2021),
 1.171.41.122a (2021), 1.171.42.56a (2022) and 1.171.42.64a (2022), Rigaku Corporation, Oxford,
 UK.
- 16 G. M. Sheldrick, SHELXT integrated space-group and crystal-structure determination, *Acta Cryst. Section A*, 2015, **71**, 3–8.
- 17 G. M. Sheldrick, Crystal structure refinement with SHELXL, Acta Cryst. Section C, 2015, 71, 3–8.

- 18 O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J.A.K. Howard and H. Puschmann, OLEX2: a complete structure solution, refinement and analysis program, *J. Appl. Cryst.*, 2009, **42**, 339–341.
- 17 J.-D. Chai, M. Head-Gordon, Phys. Chem. Chem. Phys. 2008, 10, 6615-6620.
- 18 Gaussian 16, Revision C.01, M. J. Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, G. A. Petersson, H. Nakatsuji, X. Li, M. Caricato, A. V. Marenich, J. Bloino, B. G. Janesko, R. Gomperts, B. Mennucci, H. P. Hratchian, J. V. Ortiz, A. F. Izmaylov, J. L. Sonnenberg, D. Williams-Young, F. Ding, F. Lipparini, F. Egidi, J. Goings, B. Peng, A. Petrone, T. Henderson, D. Ranasinghe, V. G. Zakrzewski, J. Gao, N. Rega, G. Zheng, W. Liang, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, K. Throssell, J. A. Montgomery, Jr., J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, T. A. Keith, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, J. M. Millam, M. Klene, C. Adamo, R. Cammi, J. W. Ochterski, R. L. Martin, K. Morokuma, O. Farkas, J. B. Foresman, and D. J. Fox, Gaussian, Inc., Wallingford CT, *2016*.
- 19 A. V. Marenich, C. J. Cramer, D. G. Truhlar, J. Phys. Chem. B, 2009, 113, 6378–6396.